Phase I study of flavopiridol [alvocidib] in combination with imatinib mesylate (STI571, Gleevec) in Bcr/Abl+ hematological malignancies

Trial Profile

Phase I study of flavopiridol [alvocidib] in combination with imatinib mesylate (STI571, Gleevec) in Bcr/Abl+ hematological malignancies

Completed
Phase of Trial: Phase I

Latest Information Update: 03 May 2010

At a glance

  • Drugs Alvocidib (Primary) ; Imatinib (Primary)
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Chronic myeloid leukaemia
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 03 May 2010 Actual patient number (22) added as reported by ClinicalTrials.gov.
    • 09 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top